Osimertinib-induced severe bilateral pneumothorax: A case report
He Li,Xiaojuan Shi,Gang Chen,Dongchang Wang
DOI: https://doi.org/10.1097/md.0000000000036994
IF: 1.6
2024-01-20
Medicine
Abstract:Lung cancer is the most prevalent malignant tumor and the primary cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for 80% of all lung cancer cases. [ 1–3 ] NSCLC is the most common histological type and has a poor prognosis. Stage IV NSCLC is associated with a 5-year survival rate of ~1%. [ 4 ] The discovery of driver mutations has drastically changed clinical practice in patients with lung tumors. Multiplexed testing contributes to physicians' selection of therapies; individuals with drivers receiving a matched targeted agent live longer at the same time. [ 5 ] Osimertinib is a third-generation irreversible oral epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and epidermal growth factor receptor (EGFR) T790M resistance mutations. [ 6 , 7 ] The previous trials have shown that osimertinib is associated with significantly improved efficacy and a favorable safety profile in patients with EGFR mutation-positive, locally advanced, or metastatic NSCLC, both as a first-line treatment and as a second-line treatment for progression after first-line EGFR-TKI treatment. [ 8 , 9 ] Moreover, EGFR T790M mutation-positive advanced NSCLC patients with poor performance status could benefit from osimertinib therapy. [ 10 ] However, in addition to providing an excellent survival benefit, tyrosine kinase inhibitors (TKIs) can also induce adverse events, which is a major management challenge for patients with advanced NSCLC. TKI-related adverse events such as diarrhea, paronychia, rash, decreased platelet count, decreased appetite, interstitial lung disease (ILD), and pneumothorax are commonly reported. [ 11–13 ] Drug-related lung damage, including drug-related pneumonia, pneumothorax, and diffuse alveolar hemorrhage, is a particularly worrisome adverse event. Herein, we report a case of lung adenocarcinoma with multiple metastases that developed severe bilateral spontaneous pneumothorax when treated with osimertinib as first-line treatment and died of multiple organ failure.
medicine, general & internal